A board to discuss future MS therapies in early stage (Phase I or II) trials.


Postby NHE » Sat Jan 03, 2009 2:48 pm

Although it doesn't specifically mention MS...

From MIT's Technology Review, v. 112/no. 1, January 2009.

Cells clean up unneeded proteins by shipping them to a structure called the proteasome, which chops them up. If the proteasome can't do its job, the cell eventually dies. By targeting a specific component of the structure, Proteolix has developed a proteasome inhibitor that is particularly deadly to cancer cells. In the right dose, it kills cancer with little damage to healthy tissue. A variation on the molecule targets the proteasomes in immune cells (which differ from those in normal cells), disrupting biochemical pathways that cause autoimmune disorders.

Note: The immune related work must be particularly early in its development as I wasn't able to find any mention of it on their "news" page.
User avatar
Volunteer Moderator
Posts: 3726
Joined: Sat Nov 20, 2004 3:00 pm


Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service